Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin EffectReport as inadecuate




Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect - Download this document for free, or read online. Document in PDF available to download.

Disease Markers - Volume 2016 2016, Article ID 6248264, 8 pages -

Research Article

Laboratory of Biochemistry LR12ES05 -Nutrition-Aliment Fonctionnel et Santé vasculaire-, Faculty of Medicine, University of Monastir, Monastir, Tunisia

Laboratory of Biochemistry, CHU Thar Sfar, Mahdia, Tunisia

Laboratory of Endocrinology, CHU Thar Sfar, Mahdia, Tunisia

Received 21 June 2016; Revised 27 August 2016; Accepted 19 September 2016

Academic Editor: Eugene H. J. M. Jansen

Copyright © 2016 Mohamed Haddad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Metabolic syndrome MetS is considered one of the most important public health problems. Several and controversial studies showed that the role of advanced glycation end products AGEs and their receptor in the development of metabolic syndrome and therapeutic pathways is still unsolved. We have investigated whether plasma pentosidine, carboxymethyl-lysine CML, and soluble receptor for advanced glycation end products sRAGE levels were increased in patients with MetS and the effect of metformin in plasma levels of pentosidine, CML, and sRAGE. 80 control subjects and 86 patients were included in this study. Pentosidine, CML, and sRAGE were measured in plasma by enzyme-linked immunosorbent assay ELISA. Plasma pentosidine, CML, and sRAGE levels were significantly increased in patients compared to control subjects , , and , resp

Plasma levels of pentosidine were significantly decreased in patients who received metformin compared to untreated patients . However, there was no significant difference between patients treated with metformin and untreated patients in plasma CML levels. Plasma levels of sRAGE were significantly increased in patients who received metformin and ACE inhibitors and , resp

However, in a multiple stepwise regression analysis, pentosidine, sRAGE, and drugs treatments were not independently associated. Patients with metabolic syndrome showed increased levels of AGEs such as pentosidine and CML. Metformin treatment showed a decreased level of pentosidine but not of CML. Therapeutic pathways of AGEs development should be taken into account and further experimental and in vitro studies merit for advanced research.





Author: Mohamed Haddad, Ines Knani, Hsan Bouzidi, Olfa Berriche, Mohamed Hammami, and Mohsen Kerkeni

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents